A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study
Gut and Liver
;
: 607-614, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-216110
ABSTRACT
BACKGROUND/AIMS:
Proton pump inhibitors (PPIs) act by irreversibly binding to the H+-K+-ATPase of the proton pump in parietal cells and may possibly affect the vacuolar H+-ATPase in osteoclasts.METHODS:
We investigated the effect of 8 weeks of PPI treatment on the parameters of bone turnover and compared PPI with revaprazan, which acts by reversibly binding to H+-K+-ATPase in proton pumps. This study was a parallel randomized controlled trial. For 8 weeks, either a PPI or revaprazan was randomly assigned to patients with gastric ulcers. The parameters of bone turnover were measured at the beginning of and after the 8-week treatment period.RESULTS:
Twenty-six patients (PPI, n=13; revaprazan, n=13) completed the intention-to-treat analysis. After the 8-week treatment period, serum calcium and urine deoxypyridinoline (DPD) were increased in the PPI group (serum calcium, p=0.046; urine DPD, p=0.046) but not in the revaprazan group. According to multivariate linear regression analysis, age > or =60 years was an independent predictor for the changes in serum calcium and urine DPD.CONCLUSIONS:
In elderly patients, administering a PPI for 8 weeks altered bone parameters. Our study suggested that PPIs might directly alter bone metabolism via the vacuolar H+-ATPase in osteoclasts.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Osteoclastos
/
Pirimidinonas
/
Huesos
/
Modelos Lineales
/
Calcio
/
Análisis Multivariante
/
Estudios Prospectivos
/
Remodelación Ósea
/
Tetrahidroisoquinolinas
/
Inhibidores de la Bomba de Protones
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio observacional
/
Estudio pronóstico
Límite:
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Gut and Liver
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS